Table 6 Correlates of serum PON1 activity (U/L) in HD patients (n = 93).
Parameter | Unadjusted percent change in PON1activity | Adjusted percent change in PON1activitya | ||
|---|---|---|---|---|
βb ± SE | P-value | β ± SE | P-value | |
Clinical data | ||||
Male sex | 6.6 ± 7.4 | 0.375 | 4.7 ± 7.4 | 0.527 |
Age (per 10 years) | 1.7 ± 2.5 | 0.490 | − 0.99 ± 2.93 | 0.737 |
Living in the rural area | 10.0 ± 7.8 | 0.215 | 9.6 ± 8 | 0.233 |
RRT duration (per 1 year) | 0.2 ± 0.8 | 0.829 | − 0.29 ± 0.89 | 0.743 |
LF-HD | − 7.9 ± 9.9 | 0.428 | − 5 ± 10.1 | 0.623 |
Diabetic nephropathy | 4.4 ± 9.0 | 0.628 | 1.5 ± 8.9 | 0.869 |
Coronary heart disease | − 0.2 ± 8.2 | 0.983 | − 4.7 ± 8.2 | 0.572 |
Myocardial infarction | − 1.7 ± 9.9 | 0.866 | − 1.8 ± 9.9 | 0.856 |
Ischemic cerebral stroke | 20.5 ± 12.2 | 0.096 | 16 ± 12.4 | 0.201 |
Mean arterial pressure (per 10 mmHg) | 0.72 ± 2.89 | 0.804 | 1.7 ± 3.0 | 0.571 |
Dry body mass (per 10 kg) | − 1.0 ± 2.3 | 0.659 | − 1.6 ± 2.5 | 0.510 |
Body mass index (per 5 kg/m2) | 0.2 ± 3.9 | 0.963 | − 0.7 ± 4.0 | 0.851 |
Cigarette smoking | 21.1 ± 12.2 | 0.086 | 24.4 ± 12.4 | 0.052 |
Urine output (per 300 mL/day) | − 1.2 ± 2.1 | 0.552 | − 2.0 ± 2.0 | 0.339 |
Lipid-modifying treatment | 7.5 ± 8.3 | 0.371 | 6.0 ± 8.2 | 0.467 |
- treatment with statins | 7.3 ± 8.4 | 0.389 | 6.6 ± 8.3 | 0.429 |
Treatment with antihypertensive drugs | 8.0 ± 7.3 | 0.276 | 12.5 ± 7.3 | 0.093 |
Treatment with phosphate binding agents | 4.7 ± 10.2 | 0.648 | 6.2 ± 10.1 | 0.540 |
Treatment with calcium-based phosphate binders | 4.7 ± 10.2 | 0.648 | 6.2 ± 10.1 | 0.540 |
Treatment with vitamin D (alfacalcidol–2 cases) or vitamin D analogs (paricalcitol—5 cases) | − 5.0 ± 13.8 | 0.716 | − 7.9 ± 14.3 | 0.583 |
Treatment with ESA | 5.0 ± 8.0 | 0.532 | 6.7 ± 7.9 | 0.401 |
ESA dose (per 1 µg/kg/week) | 0.036 ± 0.029 | 0.217 | 0.041 ± 0.028 | 0.150 |
Treatment with cinacalcet | − 5.3 ± 14.9 | 0.721 | 0.1 ± 14.7 | 0.995 |
Vitamin C supplementation | 7.6 ± 25.2 | 0.763 | 6.3 ± 24.6 | 0.799 |
Zinc supplementation | 27.1 ± 20.5 | 0.189 | 29.8 ± 20.7 | 0.155 |
Green tea intake | − 0.1 ± 18.0 | 0.997 | 3.2 ± 17.9 | 0.858 |
Type of dyslipidaemia by K/DOQI | ||||
Hyper-LDL-cholesterolemic | 7.25 ± 7.36 | 0.328 | 5.4 ± 7.3 | 0.467 |
Hyper-TG/hyper-non-HDL-cholesterolemic | 6.48 ± 16.18 | 0.690 | 9.3 ± 16.6 | 0.577 |
Mixed | − 21.4 ± 10.0 | 0.035 | − 16.4 ± 10.1 | 0.109 |
Non-dyslipidemic | 2.72 ± 7.53 | 0.719 | 1.3 ± 7.5 | 0.861 |
Atherogenic dyslipidaemia | − 5.25 ± 7.38 | 0.479 | − 7.5 ± 7.5 | 0.323 |
Laboratory data | ||||
Total cholesterol (per 10 mg/dL) | − 1.0 ± 0.6 | 0.066 | − 0.77 ± 0.56 | 0.170 |
HDL cholesterol (per 10 mg/dL) | − 3.9 ± 3.1 | 0.218 | − 1.7 ± 3.4 | 0.610 |
LDL cholesterol (per 10 mg/dL) | 0.31 ± 0.63 | 0.625 | − 0.20 ± 0.62 | 0.752 |
TG (per 10 mg/dL) | − 1.06 ± 0.49 | 0.034 | − 0.94 ± 0.48 | 0.056 |
Non-HDL-cholesterol (per 10 mg/dL) | − 0.91 ± 0.56 | 0.108 | − 0.71 ± 0.55 | 0.204 |
LDL/HDL cholesterol (per 1.0) | 0.79 ± 1.79 | 0.658 | 0.67 ± 1.81 | 0.712 |
HDL/TC (per 5%) | 41.0 ± 42.1 | 0.332 | 46.4 ± 42 | 0.272 |
TG/HDL-cholesterol (per 1.0) | − 1.5 ± 1.4 | 0.288 | − 1.8 ± 1.4 | 0.206 |
Creatinine (per 1 mg/dL) | − 0.66 ± 1.57 | 0.674 | − 1.2 ± 2.0 | 0.551 |
Urea (per 10 mg/dL) | − 0.35 ± 0.99 | 0.723 | 0.53 ± 1.10 | 0.628 |
C-reactive protein (per 1 mg/L) | − 0.25 ± 0.28 | 0.370 | − 0.40 ± 0.28 | 0.150 |
Albumin (per 1 g/dL) | 5.3 ± 10.4 | 0.609 | 3.1 ± 10.4 | 0.767 |
Total calcium (per 1 mg/dL) | − 1.2 ± 4.1 | 0.774 | − 1.1 ± 4.1 | 0.783 |
Phosphorus (per 1 mg/dL) | − 3.9 ± 2.0 | 0.060 | − 4.0 ± 2.0 | 0.054 |
Total ALP (per 100 IU/L) | 6.6 ± 6.3 | 0.295 | 5.5 ± 6.5 | 0.394 |
Parathyroid hormone (per 1000 pg/mL) | 2.0 ± 8.2 | 0.807 | 1.9 ± 8.6 | 0.830 |
Haemoglobin (per 1 g/dL) | 1.7 ± 2.9 | 0.546 | 1.4 ± 2.8 | 0.628 |
